$3.200
+0.470 (+14.70%)Zum Schluss
FEMY-News
FEMY-Events
Femasys Partners with UNC Health to Launch Fertility Diagnostics
Femasys announced a partnership with UNC Health to introduce its female and male fertility diagnostics, FemVue and SpermVue, together with FemaSeed Complete, an in-office intratubal insemination solution designed as a first-line fertility treatment, within UNC Health OB/GYN practice locations.
Femasys FemBloc Receives FDA Approval
Femasys announced that the FDA has approved the company's modular premarket approval application pathway for FemBloc, its investigational non-surgical permanent birth control technology in the United States. FemBloc is approved for marketing in Europe and other select international markets.
Femasys Secures FemBloc Patent in US and International Markets
Femasys announced the issuance of patents in the United States and key international markets that expand intellectual property protection for the blended polymer component of FemBloc, the company's non-surgical permanent birth control technology.
Femasys Enters $30M Private Placement Agreement
Femasys announced that it has entered into a securities purchase agreement for a $30M private placement with certain accredited investors. The financing was led by new institutional investor Nantahala Capital, with participation from additional new healthcare-focused funds, including Rosalind Advisors, as well as members of Femasys' management team. The private placement is subject to customary closing conditions and is expected to close on or around August 10. Laidlaw & Company Ltd. acted as placement agent for the private placement. Pursuant to the terms of the Purchase Agreement, the Company is selling to the investors an aggregate of 9,374,999 shares of the Company's Common Stock and pre-funded warrants to purchase shares of the Company's Common Stock, together with accompanying warrants to purchase an aggregate of 18,749,998 shares of the Company's Common Stock. For each share of Common Stock or pre-funded warrant purchased, each investor will receive two accompanying warrants with a term of three years: (i) a warrant to purchase an aggregate of 9,374,999 shares of common stock and (ii) a milestone warrant to purchase an aggregate of 9,374,999 shares of common stock. The purchase price per share of Common Stock and accompanying warrants is $3.20 and the purchase price per pre-funded warrants and accompanying warrants is $3.1999. Each pre-funded warrant has an exercise price of $0.0001 per share. The exercise price of the accompanying warrants is $2.95 per share. If all of the warrants are exercised for cash, the Company would receive up to an additional $60M in potential proceeds upon full cash exercise of the warrants, which exercise is at each holder's discretion and, with respect to the milestone warrants, subject to the Company's achievement of specified revenue and share price milestones, described below. The milestone warrants will become exercisable beginning 12 months following the closing and will expire 45 days after the Company's achievement of (i) reported U.S. revenue of at least $1.5 million in any fiscal quarter, (ii) the daily volume weighted average price of its common stock equal to or greater than 130% of the milestone warrant exercise price on at least 20 trading days during any 30-consecutive-trading-day period, (iii) the daily volume weighted average price of its common stock on such date is equal to or greater than 130% of the milestone warrant exercise price, and (iv) an effective resale registration statement.
Femasys Receives CE Mark Approval for FemHSG Catheter
Femasys announced CE Mark approval for its FemHSG Catheter, further expanding the company's portfolio in Europe through commercial partners.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.